Observational analysis
Study theme · illustration
Read the results alongside the study design, safety findings and limitations.

Who was studied?

101 patients: chemotherapy combination 35, TKI combination 36, PRaG 30.

What does the publication report?

The PRaG group had ORR 20.0% and median PFS 4.5 months; no significant OS difference was found between groups.

Safety findings

The full text reports any-grade and grade 3 adverse-reaction rates of 66.7% and 16.7% in the 30-patient PRaG group, versus 77.1%/28.6% with chemotherapy and 58.3%/13.9% with TKIs. Nonrandom treatment allocation prevents causal safety comparisons.

How should we interpret it?

Nonrandomized treatment selection can confound comparisons. The absence of an OS difference must be retained when interpreting the PFS finding.

Read the original source

This independently written summary was checked against the original full publication. It is an educational summary, not a full-paper translation or clinical recommendation.

Efficacy of PRaG therapy in microsatellite-stable metastatic colorectal cancer: a comparative analysis of PD-1/PD-L1 inhibitor-based combination therapies · DOI: 10.1007/s00262-025-04185-y · PMID: 41051603

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.